Literature DB >> 1660255

Varicella-zoster virus latency.

K D Croen1, S E Straus.   

Abstract

Entities:  

Mesh:

Year:  1991        PMID: 1660255     DOI: 10.1146/annurev.mi.45.100191.001405

Source DB:  PubMed          Journal:  Annu Rev Microbiol        ISSN: 0066-4227            Impact factor:   15.500


× No keyword cloud information.
  5 in total

1.  Analysis of individual human trigeminal ganglia for latent herpes simplex virus type 1 and varicella-zoster virus nucleic acids using real-time PCR.

Authors:  R J Cohrs; J Randall; J Smith; D H Gilden; C Dabrowski; H van Der Keyl; R Tal-Singer
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  The cellular localization pattern of Varicella-Zoster virus ORF29p is influenced by proteasome-mediated degradation.

Authors:  Christina L Stallings; Gregory J Duigou; Anne A Gershon; Michael D Gershon; Saul J Silverstein
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  Acyclovir for varicella in immunocompetent patients.

Authors:  J L Kimpen; H S Heymans
Journal:  Clin Investig       Date:  1993-06

4.  Posttranslational modification and cell type-specific degradation of varicella-zoster virus ORF29p.

Authors:  Christina L Stallings; Saul J Silverstein
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

5.  Immunization with the immediate-early tegument protein (open reading frame 62) of varicella-zoster virus protects guinea pigs against virus challenge.

Authors:  C Sabella; P W Lowry; G M Abbruzzi; C M Koropchak; P R Kinchington; M Sadegh-Zadeh; J Hay; W T Ruyechan; A M Arvin
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.